Systematic review evaluates efficacy and safety of efgartigimod in myasthenia gravis, suggesting differences based on antibody subtype.
To evaluate the efficacy and safety of efgartigimod in patients with myasthenia gravis (MG) and to determine whether response differs between AChR-positive and AChR-negative subtypes.
No takes yet. Share an insight, caveat, or question.
Sabet et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: